Lamotrigine ODT FDA Approval Boosts Sale

  Published 1 month ago

Alembic's Lamotrigine ODT gained FDA ANDA approval, therapeutically equivalent to GlaxoSmithKline's Lamictal for epilepsy treatment.

  • Indicated for adjunctive therapy in patients aged two and older with various seizure types including.
  • Approved for conversion to monotherapy in adults switching from carbamazepine, phenytoin, phenobarbital, primidone, or valproate.
  • Market size estimated US$27 million for twelve months ending December 2025, per IQVIA data in USA.

You might like these

India Expands Wheat, Sugar Exports 2026

UCB Capital Raising: RBI Discussion Paper

HCLTech Falls on Margin Cut

Eternal Shares Dive Amid CEO Switch and Profit Spike

Rajasthan Rs 3,700 Crore Project Launch

China's Exports Slow, Deflation Worsens Amid U.S. Tariffs

Voltas Shares Surge on Axis Direct 'Buy' Rating

News that matters the most ⚡